786 related articles for article (PubMed ID: 15190138)
21. Epstein-Barr virus DNA quantification and follow-up in Tunisian nasopharyngeal carcinoma patients.
Hassen E; Farhat K; Gabbouj S; Bouaouina N; Abdelaziz H; Chouchane L
Biomarkers; 2011 May; 16(3):274-80. PubMed ID: 21506698
[TBL] [Abstract][Full Text] [Related]
22. [The clinical value of quantitative analysis of plasma Epstein-Barr virus DNA in patients with nasopharyngeal carcinoma].
Yuan H; Yang BB; Xu ZF
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2004 Mar; 39(3):162-5. PubMed ID: 15283296
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma.
Shao JY; Zhang Y; Li YH; Gao HY; Feng HX; Wu QL; Cui NJ; Cheng G; Hu B; Hu LF; Ernberg I; Zeng YX
Anticancer Res; 2004; 24(6):4059-66. PubMed ID: 15736452
[TBL] [Abstract][Full Text] [Related]
24. [Correlation between the kinetics of plasma EBV DNA levels and clinical response during treatment in patients with nasopharyngeal carcinoma].
Peng PJ; Zhao C; Liao H; Wang FQ; Zhang L
Ai Zheng; 2002 Aug; 21(8):817-22. PubMed ID: 12478884
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA.
Chan AT; Ma BB; Lo YM; Leung SF; Kwan WH; Hui EP; Mok TS; Kam M; Chan LS; Chiu SK; Yu KH; Cheung KY; Lai K; Lai M; Mo F; Yeo W; King A; Johnson PJ; Teo PM; Zee B
J Clin Oncol; 2004 Aug; 22(15):3053-60. PubMed ID: 15284255
[TBL] [Abstract][Full Text] [Related]
26. Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels.
Wang WY; Twu CW; Chen HH; Jiang RS; Wu CT; Liang KL; Shih YT; Chen CC; Lin PJ; Liu YC; Lin JC
Cancer; 2013 Mar; 119(5):963-70. PubMed ID: 23065693
[TBL] [Abstract][Full Text] [Related]
27. Quantitative analysis of the transrenal excretion of circulating EBV DNA in nasopharyngeal carcinoma patients.
Chan KC; Leung SF; Yeung SW; Chan AT; Lo YM
Clin Cancer Res; 2008 Aug; 14(15):4809-13. PubMed ID: 18676752
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma.
Lei KI; Chan LY; Chan WY; Johnson PJ; Lo YM
Clin Cancer Res; 2002 Jan; 8(1):29-34. PubMed ID: 11801537
[TBL] [Abstract][Full Text] [Related]
29. Quantitative Epstein-Barr virus DNA analysis and detection of gene promoter hypermethylation in nasopharyngeal (NP) brushing samples from patients with NP carcinoma.
Tong JH; Tsang RK; Lo KW; Woo JK; Kwong J; Chan MW; Chang AR; van Hasselt CA; Huang DP; To KF
Clin Cancer Res; 2002 Aug; 8(8):2612-9. PubMed ID: 12171892
[TBL] [Abstract][Full Text] [Related]
30. Clinical value of Epstein-Barr virus DNA levels in peripheral blood samples of Italian patients with undifferentiated carcinoma of nasopharyngeal type.
Bortolin MT; Pratesi C; Dolcetti R; Bidoli E; Vaccher E; Zanussi S; Tedeschi R; De Paoli P
Cancer Lett; 2006 Feb; 233(2):247-54. PubMed ID: 15907367
[TBL] [Abstract][Full Text] [Related]
31. Plasma Epstein-Barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma.
Hsu CL; Chang KP; Lin CY; Chang HK; Wang CH; Lin TL; Liao CT; Tsang NM; Lee LY; Chan SC; Ng SH; Li HP; Chang YS; Wang HM
Head Neck; 2012 Aug; 34(8):1064-70. PubMed ID: 22083949
[TBL] [Abstract][Full Text] [Related]
32. Can plasma Epstein-Barr virus DNA levels be used to monitor nasopharyngeal carcinoma progression?
Farrell PJ
Nat Clin Pract Oncol; 2005 Jan; 2(1):14-5. PubMed ID: 16264847
[No Abstract] [Full Text] [Related]
33. Disparity of sensitivities in detection of radiation-naïve and postirradiation recurrent nasopharyngeal carcinoma of the undifferentiated type by quantitative analysis of circulating Epstein-Barr virus DNA1,2.
Leung SF; Lo YM; Chan AT; To KF; To E; Chan LY; Zee B; Huang DP; Johnson PJ
Clin Cancer Res; 2003 Aug; 9(9):3431-4. PubMed ID: 12960133
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma.
Lu JJ; Shakespeare TP; Tan LK; Goh BC; Cooper JS
Head Neck; 2004 May; 26(5):389-95. PubMed ID: 15122654
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC).
Liu MT; Yeh CY
Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898
[TBL] [Abstract][Full Text] [Related]
36. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA.
Lo YM; Chan AT; Chan LY; Leung SF; Lam CW; Huang DP; Johnson PJ
Cancer Res; 2000 Dec; 60(24):6878-81. PubMed ID: 11156384
[TBL] [Abstract][Full Text] [Related]
37. Prospective validation of serum CYFRA 21-1, beta-2-microglobulin, and ferritin levels as prognostic markers in patients with nonmetastatic nasopharyngeal carcinoma undergoing radiotherapy.
Ma BB; Leungm SF; Hui EP; Mo F; Kwan WH; Zee B; Yuen J; Chan AT
Cancer; 2004 Aug; 101(4):776-81. PubMed ID: 15305409
[TBL] [Abstract][Full Text] [Related]
38. Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma.
Gandhi MK; Lambley E; Burrows J; Dua U; Elliott S; Shaw PJ; Prince HM; Wolf M; Clarke K; Underhill C; Mills T; Mollee P; Gill D; Marlton P; Seymour JF; Khanna R
Clin Cancer Res; 2006 Jan; 12(2):460-4. PubMed ID: 16428487
[TBL] [Abstract][Full Text] [Related]
39. Validation of Roche LightCycler Epstein-Barr virus quantification reagents in a clinical laboratory setting.
Gulley ML; Fan H; Elmore SH
J Mol Diagn; 2006 Nov; 8(5):589-97. PubMed ID: 17065428
[TBL] [Abstract][Full Text] [Related]
40. Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma.
To EW; Chan KC; Leung SF; Chan LY; To KF; Chan AT; Johnson PJ; Lo YM
Clin Cancer Res; 2003 Aug; 9(9):3254-9. PubMed ID: 12960110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]